155 related articles for article (PubMed ID: 21301935)
1. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
Banks SL; Paudel KS; Brogden NK; Loftin CD; Stinchcomb AL
Pharm Res; 2011 May; 28(5):1211-9. PubMed ID: 21301935
[TBL] [Abstract][Full Text] [Related]
2. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
3. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
4. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.
Banks SL; Pinninti RR; Gill HS; Paudel KS; Crooks PA; Brogden NK; Prausnitz MR; Stinchcomb AL
J Pharm Sci; 2010 Jul; 99(7):3072-80. PubMed ID: 20166200
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
7. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
Banks SL; Pinninti RR; Gill HS; Crooks PA; Prausnitz MR; Stinchcomb AL
Pharm Res; 2008 Jul; 25(7):1677-85. PubMed ID: 18449628
[TBL] [Abstract][Full Text] [Related]
8. Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.
Ghosh P; Lee D; Kim KB; Stinchcomb AL
Pharm Res; 2014 Jan; 31(1):148-59. PubMed ID: 23943543
[TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
[TBL] [Abstract][Full Text] [Related]
10. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
Milewski M; Stinchcomb AL
Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
[TBL] [Abstract][Full Text] [Related]
11. Vehicle influence on permeation through intact and compromised skin.
Gujjar M; Banga AK
Int J Pharm; 2014 Sep; 472(1-2):362-8. PubMed ID: 24979534
[TBL] [Abstract][Full Text] [Related]
12. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
13. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.
Valiveti S; Paudel KS; Hammell DC; Hamad MO; Chen J; Crooks PA; Stinchcomb AL
Pharm Res; 2005 Jun; 22(6):981-9. PubMed ID: 15948042
[TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs.
Valiveti S; Hammell DC; Paudel KS; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2005 Feb; 102(2):509-20. PubMed ID: 15653167
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.
Kiptoo PK; Paudel KS; Hammell DC; Hamad MO; Crooks PA; Stinchcomb AL
Eur J Pharm Sci; 2008 Apr; 33(4-5):371-9. PubMed ID: 18321686
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
17. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin.
Liu S; Jin MN; Quan YS; Kamiyama F; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Eur J Pharm Biopharm; 2014 Feb; 86(2):267-76. PubMed ID: 24120887
[TBL] [Abstract][Full Text] [Related]
18. Diclofenac delays micropore closure following microneedle treatment in human subjects.
Brogden NK; Milewski M; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Control Release; 2012 Oct; 163(2):220-9. PubMed ID: 22929967
[TBL] [Abstract][Full Text] [Related]
19. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.
Milewski M; Yerramreddy TR; Ghosh P; Crooks PA; Stinchcomb AL
J Control Release; 2010 Aug; 146(1):37-44. PubMed ID: 20678989
[TBL] [Abstract][Full Text] [Related]
20. Fabrication, Physicochemical Characterization, and Performance Evaluation of Biodegradable Polymeric Microneedle Patch System for Enhanced Transcutaneous Flux of High Molecular Weight Therapeutics.
Shah V; Choudhury BK
AAPS PharmSciTech; 2017 Nov; 18(8):2936-2948. PubMed ID: 28432615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
